Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × abemaciclib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 91 Neoplasm Metastasis 11 Triple Negative Breast Neoplasms 5 Neoplasms 5 Breast Diseases 4 Unilateral Breast Neoplasms 2 Recurrence 2 Pancreatic Neoplasms 2 Neoplasms by Site 2 Lymphoma, Non-Hodgkin 2 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms, Male 2 Breast Cancer Female 2 Brain Neoplasms 2 Venous Thromboembolism 1 Thrombocytosis 1 Solid Tumor 1 Sarcoma 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasm, Residual 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Mesothelioma, Malignant 1

Interventions

palbociclib 2 Trastuzumab 2 Capecitabine 2 trastuzumab deruxtecan 1 tetrathiomolybdate 1 sacituzumab govitecan 1 pembrolizumab 1 niraparib 1 inavolisib 1 giredestrant 1 eribulin 1 avelumab 1 atezolizumab 1 abemaciclib 1 Zymosan 1 Radiotherapy 1 Letrozole 1 Immunotherapy 1 Hydroxychloroquine 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05708235 2026-03-05

MiRaDoR

MedSIR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡